Abstract
Although the expression O6-methylguanine-DNA methyltransferase (MGMT) is an important hallmark for decision of nitrosourea chemotherapy for glioma patients, no immunohistochemical method for analysis of MGMT has been standardized yet. Gliomas usually contain non-neoplastic cells even deep in the tumor. It is not known which of these components expresses MGMT. To clarify this point, we investigated MGMT expression in the non-neoplastic cells in autopsy and surgical specimens by immuno-histochemistry. High grade gliomas were also studied to find a cut-off point for treatment decision. MGMT immunohistochemistry in the normal brain or brain with non-neoplastic disease revealed nuclear staining in some endothelial cells, inflammatory cells, ependymal cells, astrocytes and oligodendroglias. Some cells were double stained with CD68 (macrophages or microglias). The neurons were consistently MGMT-negative. High grade gliomas always contained an MGMT-positive non-neoplastic component. Although the endothelial cells were easily distinguished from the neoplastic cells, other cells were often mistaken for tumor cells. The population of MGMT-positive non-neoplastic cells was usually less than 10%. We set a cut off-point at 10% between the positive and negative groups because the statistical difference in the overall survival was most distinct at this value. In 51 high grade glioma patients, who received both radiotherapy and chemotherapy with nimustine (ACNU), the median overall survival of the MGMT-negative group (23months) was significantly longer than that of the MGMT-positive group (14months) (P<0.009). Multivariate analysis revealed that the negative MGMT expression was a significant prognostic variable next to the degree of surgical removal for the overall survival. In the MGMT-positive group, addition of platinum-based chemotherapy did not improve the survival.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
S Gerson (2002) ArticleTitleClinical relevance of MGMT in the treatment of cancer J Clin Oncol 20 2388–2399
M Nagane A Asai S Shibui K Nomura M Matsutani Y Kuchino (1992) ArticleTitleExpression of O6-methylguanine-DNA methyl-transferase and chloroethylnitrosourea resistance of human brain tumors Jpn J Clin Oncol 22 143–149
T Anda HK Shabani K Tsunoda Y Tokunaga M Kaminogo S Shibata T Hayashi M Iseki (2003) ArticleTitleRelationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis Neurol Res 25 241–248
M Belanich M Pastor T Randall D Guerra J Kibitel L Alas B Li M Citron P Wasserman H White H Eyre K Jaeckle S Schulman D Rector M Prados S Coons W Shapiro D Yarosh (1996) ArticleTitleRetrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine Cancer Res 56 783–788
KA Jaeckle HJ Eyre JJ Townsend S Schulman HM Knudson M Belanich DB Yarosh SI Bearman DJ Giroux SC Schold (1998) ArticleTitleCorrelation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study J Clin Oncol 16 3310–3315
K Mineura T Yanagisawa K Watanabe M Kowada N Yasui (1996) ArticleTitleHuman brain tumor O(6)-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy Int J Cancer 69 420–425
JR Silber A Blank MS Bobola S Ghatan DD Kolstoe MS Berger (1999) ArticleTitleO6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy Clin Cancer Res 5 807–814
S Tanaka I Kobayashi H Oka K Fujii T Watanabe T Nagashima T Hori (2001) ArticleTitleDrug-resistance gene expression and progression of astrocytic tumors Brain Tumor Pathol 18 131–137
S Tanaka I Kobayashi S Utsuki H Oka K Fujii T Watanabe T Nagashima T Hori (2003) ArticleTitleO6-methylguanine-DNA methyltranspherase gene expression in gliomas by means of real-time quantitative RT-PCR and clinical response to nitrosoureas Int J Cancer 103 67–72
C Komine T Watanabe Y Katayama A Yoshino T Yokoyama T Fukushima (2003) ArticleTitlePromoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytoma Brain Pathol 13 176–184
SM Lee H Reid RH Elder N Thatcher GP Margison (1996) ArticleTitleInter- and intracellular heterogeneity of O6-alkylguanine-DNA alkyltransferase expression in human brain tumors: possible significance in nitrosourea therapy Carcinogenesis 17 637–641
RE McLendon L Cleveland C Pegram SH Bigner DD Bigner HS Friedman (1998) ArticleTitleImmunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas Lab Invest 78 643–644
N Ohe M Saio M Kijima N Tamakawa T Suwa Y Kojima H Yano Y Kaku T Iwama J Shinoda N Sakai T Takami (2003) ArticleTitleIn situ detection of O6-methylguanine-DNA methyltransferase messenger RNA in paraffin-embedded human astrocytic tumor tissue by nested in situ RT-PCR is useful in predicting chemotherapy-resistance of tumors Int J Oncol 22 543–549
HS Friedman RE McLendon T Kerby M Dugan SH Bigner AJ Henry DM Ashley J Krischer S Lovell K Rasheed F Marchev AJ Seman I Cokgor J Rich E Stewart OM Colvin JM Provenzale DD Bigner MM Haglund AH Friedman PL Modrich (1998) ArticleTitleDNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma J Clin Oncol 16 3851–3857
EA Pegg (2000) ArticleTitleRepair of O6-alkylguanine by alkyltransferases Mutation Res 462 83–100
JF Costello BW Futscher K Tano DM Graunke RO Pieper (1994) ArticleTitleGraded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells J Biol Chem 269 17228–17237
M Esteller J Garcia-Foncillas E Andion SN Goodman OF Hidalgo V Vanaclocha SB Baylin JG Herman (2000) ArticleTitleInactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343 1350–1354
M Nakamura T Watanabe Y Yonekawa P Kleihues H Ohgaki (2001) ArticleTitlePromoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene Carcinogenesis 22 1715–1719
L Zhang W Lu X Miao D Xing W Tan D Lin (2003) ArticleTitleInactivation of DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma Carcinogenesis 24 1039–1044
D Yin D Xie W-K Hofmann W Zhang K Asotra R Wong KL Black HP Koeffler (2003) ArticleTitleDNA repair gene O6-methlguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors Mol Carcinog 36 23–31
M Nagane S Shibui H Oyama A Asai Y Kuchino K Nomura (1995) ArticleTitleInvestigation of chemoresistance-related genes mRNA expression for selecting anticancer agents in successful adjuvant chemotherapy for a case of recurrent glioblastoma Surg Neurol 44 462–468
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nakasu, S., Fukami, T., Baba, K. et al. Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J Neurooncol 70, 333–340 (2004). https://doi.org/10.1007/s11060-004-9170-6
Issue Date:
DOI: https://doi.org/10.1007/s11060-004-9170-6